XW001

DRUG3 trials

Sponsors

Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd.

Conditions

COVID-19 Acute Respiratory Distress SyndromeRSV InfectionRespiratory Syncytial Virus Infections

Phase 1

A Study of XW001 in Healthy Adult Subjects

CompletedNCT05642403

Hangzhou Sciwind Biosciences Co., Ltd.Respiratory Syncytial Virus Infections

Start: 2021-01-03End: 2022-06-20Updated: 2023-03-08

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

CompletedNCT05779995

Hangzhou Sciwind Biosciences Co., Ltd.RSV Infection

Start: 2023-04-20End: 2024-01-08Updated: 2025-08-17

Phase 2

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

WithdrawnNCT05083117

Sciwind Biosciences APAC CO Pty. Ltd.COVID-19 Acute Respiratory Distress Syndrome

Start: 2021-10-30End: 2022-04-10Updated: 2023-08-21